0001493152-23-022908.txt : 20230629 0001493152-23-022908.hdr.sgml : 20230629 20230629160116 ACCESSION NUMBER: 0001493152-23-022908 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230626 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERALINK TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001362703 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202590810 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52218 FILM NUMBER: 231057307 BUSINESS ADDRESS: STREET 1: 8000 INNOVATION PARK STREET 2: DR, BATON ROUGE CITY: BATON ROUGE STATE: LA ZIP: 70820 BUSINESS PHONE: 225-578-7555 MAIL ADDRESS: STREET 1: 8000 INNOVATION PARK STREET 2: DR, BATON ROUGE CITY: BATON ROUGE STATE: LA ZIP: 70820 FORMER COMPANY: FORMER CONFORMED NAME: OncBioMune Pharmaceuticals, Inc DATE OF NAME CHANGE: 20150903 FORMER COMPANY: FORMER CONFORMED NAME: QUINT MEDIA INC. DATE OF NAME CHANGE: 20130807 FORMER COMPANY: FORMER CONFORMED NAME: PediatRx Inc. DATE OF NAME CHANGE: 20101230 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2023

THERALINK TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-52218	20-2590810
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

15000 W. 6th Ave., #400

Golden, CO 80401

(Address of principal executive offices)

(888) 585-4923

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Theralink Technologies, Inc. (the “Company”) announces that Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023. Ms. Zaslavsky has served as the Company’s President and Chief Operating Officer since December 2022.

Ms. Zaslavsky has over 23 years of experience in the field of genomics and multiple commercialization successes to her credit. She has made significant contributions to the development of new genomic offerings and the application of genomics to clinical practice, ultimately making genomics more accessible to patients and healthcare providers while building corporate value. Amongst other successes, Ms. Zaslavsky has been instrumental in the commercialization of tests that detect mutations in BRCA1 and BRCA2 genes associated with increased risk of breast and ovarian cancer; provided oversight for tests used to detect mutations in genes associated with Lynch syndrome, a hereditary cancer syndrome; and launched an oncology suite of solutions providing guidance in therapeutic decision making. Cumulatively, these tests inform thousands of physicians, and help treat or prevent countless cases of cancer. Ms. Zaslavsky received a bachelor’s degree in Business Administration from Washington State University in 1997.

Ms. Zaslavsky entered into an Offer Letter with the Company on December 5, 2022, which remains in place following her new appointment.

The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.

Item 7.01 Regulation FD Disclosure.

On June 27, 2023, the Company issued a press release announcing Ms. Zaslavsky’s appointment, which is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

99.1		Press Release, dated June 27, 2023, issued by Theralink

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERALINK TECHNOLOGIES, INC.

	By:	/s/ Faith Zaslavsky
	Name:	Faith Zaslavsky
	Title:	Chief Executive Officer

Date: June 29, 2023

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer

Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.

“I am very excited to hand the reins to Faith as we take the strategic step to merge with IMAC,” commented Dr. Ruxin. “As we begin a new chapter of shifting our focus from research and development to commercialization for the Company, Faith checks all the boxes as an excellent fit for our future. She is a highly accomplished executive having previously served as president and general manager of the oncology business unit of a $2 billion dollar genetics company. A respected executive with a passion for health care innovation, Faith has unparalleled leadership ability and knowledge of international business, which will be instrumental as we move forward to help save lives with the Theralink assay for a spectrum of cancers.”

Ms. Zaslavsky has over 23 years of experience in the field of genomics and multiple commercialization successes to her credit. She has made significant contributions to the development of new genomic offerings and the application of genomics to clinical practice, ultimately making genomics more accessible to patients and healthcare providers while building corporate value. Amongst other successes, Ms. Zaslavsky has been instrumental in the commercialization of tests that detect mutations in BRCA1 and BRCA2 genes associated with increased risk of breast and ovarian cancer; provided oversight for tests used to detect mutations in genes associated with Lynch syndrome, a hereditary cancer syndrome; and launched an oncology suite of solutions providing guidance in therapeutic decision making. Cumulatively, these tests inform thousands of physicians, and help treat or prevent countless cases of cancer.

As Chief Executive Officer of Theralink, Ms. Zaslavsky will be tasked with leveraging her prior successes to spearhead commercialization of the Theralink^® Reverse Phase Protein Array assays, a next generation of genomic technology used to guide personalized cancer therapeutics.

Faith Zaslavsky stated, “On behalf of our executive leadership team, I want to thank Mick for his innumerable contributions and dedicated years of service to Theralink. Since his appointment to CEO in 2018, Mick has led the Theralink team through critical product development and business model transformations, which has enabled the Company to expand our product and intellectual property portfolio. I am honored to follow in his footsteps and embrace the opportunity to lead Theralink as we bring proprietary, life-changing testing solutions to physicians and patients facing a cancer journey.”

About Theralink Technologies, Inc.

Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and laboratory developed tests (LDTs), Theralink’s technology targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink^® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Contact:
Al kucharchuk
Al.Kucharchuk@theralink.com

EX-101.SCH 3 ther-20230626.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ther-20230626_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ther-20230626_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 26, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 26, 2023
Entity File Number	000-52218
Entity Registrant Name	THERALINK TECHNOLOGIES, INC.
Entity Central Index Key	0001362703
Entity Tax Identification Number	20-2590810
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	15000 W. 6th Ave.
Entity Address, Address Line Two	#400
Entity Address, City or Town	Golden
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80401
City Area Code	(888)
Local Phone Number	585-4923
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001362703 2023-06-26 2023-06-26 iso4217:USD shares iso4217:USD shares 0001362703 false 8-K 2023-06-26 THERALINK TECHNOLOGIES, INC. NV 000-52218 20-2590810 15000 W. 6th Ave. #400 Golden CO 80401 (888) 585-4923 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "> W58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " G@-U6TJ#_V>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TEAP=#M1?&D(+B@> O)[&ZP24,RTN[;F];=+J(/X#$S?[[Y M!J8U49DAX7,:(B9RF&\FWX>L3-RR(U%4 -DM(VGSH M X+D? ,>25M-&F9@%5)KZ%JZ &4:8?/XNH%V)2_5/[-(!=DY.V:VI<1SKL5ER90 W5:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M)X#=5I^!<[/\ P 20\ !@ !X;"]W;W)K(D\R;)S.3UW9GK?1WL^3,7.FKU.1ZUL*B2?:F)66<;TVQ5/ MU;KK4>_]Q(-8+*T[X?#4=+U D?$4QY;)\'@[X4/>)HZ)>#XL17URF>ZP-WC M=_7KXN7A99Z9X0.5/HG$+KM>Y)&$S]DJM0]J?K%*3?%+UIM[&PV/ MQ"MC5;8-!H),R,T_>]TF8B<@;.\)"+DJ\JCU7!50)SM#=0+UQW?@I0[XR]-SF+>]: ]#=/V>IX0A'L^1H'I>,*==")60H$P+-5YL77*ELHT-]U"K16JC@4%IAW\BU M2#D9K[+G^M[&-8(@.&V&(8T0GHN2Y^(8G@>^$*ZS(6=CEM4F"M>9W0X?^O>C M\=VGV7!P.Y[<3VY&P\<3,AH/SA#,J,2,CL$<0%$U2\E()OR5W/&W.E!<"9)' MSUOA18!5LUUBM8_!FK%7,DJ 3[B/3&0]&2Y)FU#G3T]GI&67I/_"L1ZDU1Q 40O'06=K50N*2WYN!&BE*_^G MN(-_9!NX$91XIM:RE@N7NU$I-#1&5DT*%'?UCV1E]TVU>A$RKJ\OKCF88&C5 M/$%Q>_^(-E7&@KW\(_+]GP2N& 6-@&)LU41!<9Q^%%S@]RB*_L!0 MJCF"XN9^KV+(RG2I)#9I'1!I1LW31AN=1&DU'5#36=$TM M%2YT:,E!JZF XL[]J%(1"ROD@GR%!M>"I;4\N,HAGK"R_A WYZGFIS&DA\,7 MMED9PN(,UK"3^;R^?@?T#I)5?A_BYOP+V@6;+F:Q=Z5G96'G51PN8:_+M;L!KL^5LN\#M_TJ=\^]_P%02P,$% @ )X#=5I^@ M&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8 MMD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2 M_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQD MB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G M8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E M#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-C MT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/C MO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,, MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@ M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$ M% @ )X#=5I>*NQS $P( L !?3T\$MP>:4#M.*2V MBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YV MX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!E MK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3 M(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,. M]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$ M% @ )X#=5B0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*] M:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8V MP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X! M4$L#!!0 ( "> W59ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-= M+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5 MA4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0 M]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K M'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+* M&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>= M(\G=560C2&2FKW@ALO7L^T%.6X.^DT K @ $0 @ &O 9&]C4')O<',O8V]R M92YX;6Q02P$"% ,4 " G@-U6F5R<(Q & "<)P $P M@ '+ 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( "> W5:?@7.S M_ , $D/ 8 " @0P( !X;"]W;W)K&PO W5:7BKL

MW5:JQ"(6,P$ "(" / " 0,0 !X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " G@-U6)!Z;HJT #X 0 &@ @ %C M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " G@-U6 M99!YDAD! #/ P $P @ %($@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" "2$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://theralink.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ther-20230626.xsd ther-20230626_lab.xml ther-20230626_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ther-20230626_lab.xml" ] }, "presentationLink": { "local": [ "ther-20230626_pre.xml" ] }, "schema": { "local": [ "ther-20230626.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "THER", "nsuri": "http://theralink.com/20230626", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://theralink.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-06-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://theralink.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001493152-23-022908-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-022908-xbrl.zip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end